Compare Sana Biotechnology Inc (SANA) vs White Mountains Insurance Group Ltd. Common Stock (WTM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs White Mountains Insurance Group Ltd. Common Stock — how do they compare? Sana Biotechnology Inc trades at $2.33 (market cap $697.51M), while White Mountains Insurance Group Ltd. Common Stock trades at $2,090 (market cap $5.01B). The key difference: White Mountains Insurance Group Ltd. Common Stock is far larger — about 7.2× Sana Biotechnology Inc's market cap, and White Mountains Insurance Group Ltd. Common Stock pays a 0.05% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | WTM | |
|---|---|---|
Market Cap | $697.51M | $5.01B |
Volume | 2,763,583 | 19,324 |
Sector | Health | Financials |
52-Week High | $5.92 | $2.32K |
52-Week Low | $2.33 | $1.85K |
Typical Hold Time | 24 Days | — |
Enterprise Value | $610.76M | $5.84B |
Dividend Yield | — | 0.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sana Biotechnology (SANA) trades at $2.41, down 8.02% in the last session, reflecting a bearish technical trend despite bullish oscillators. The company is pre-revenue with significant losses, reporting a net income of -$244.17 million in 2025 and negative cash flow, while maintaining a price-to-book ratio of 4.51. Recent news highlights active participation in investor conferences and a positive analyst consensus.
The outlook is speculative, with high risk due to no current revenue and substantial cash burn, but potential upside exists if clinical developments succeed, supported by an analyst consensus price target of $8.50. Key risks include funding needs, clinical trial outcomes, and competitive pressures in biotechnology.
White Mountains Insurance Group (WTM) trades at $2,093.13, up 0.31% with neutral technical signals. The stock shows strong fundamentals with a P/E of 4.8 and ROE of 21.9%, though recent earnings were mixed with Q2 2026 beating estimates while Q1 missed. Book value per share reached $2,258 as of June 2026, up 4% quarterly. Recent product launches and board additions signal strategic growth initiatives.
WTM presents value investment appeal with attractive valuation multiples and solid profitability, but faces execution risks from volatile quarterly earnings and negative cash flow trends. Analyst consensus remains neutral with 100% hold ratings, suggesting cautious optimism pending clearer earnings consistency and cash flow improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About White Mountains Insurance Group Ltd. Common Stock
White Mountains Insurance Group Ltd. is a Bermuda-based holding company that owns and builds insurance and financial services businesses. Its operating segments include Ark, a specialty insurance and reinsurance underwriter; HG Global, which reinsures municipal bond insurer Build America Mutual; and Kudu Investment Management, which provides capital to boutique asset managers.
Read more on WTM →
